Widening the PDE-10 landscape

elbion N.V. was to announce on Monday this week that it will co-develop its discovery stage phosphodiesterase-10 inhibitors for schizophrenia and other CNS disorders with Wyeth. The deal adds WYE to a handful of pharma companies that have disclosed work on PDE-10 inhibitors. It also will provide resources for elbion to advance its internal and newly acquired products.

The companies will collaborate on optimization and preclinical development. WYE (Madison, N.J.) received rights for clinical development and commercialization. elbion will receive an undisclosed upfront payment and research funding and is eligible for milestones, all of which could total $110 million, plus royalties. ...